Printer Friendly

Research and Markets: HIV/AIDS Therapeutics Market to 2018.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/cnk25v/hivaids) has announced the addition of the "HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth" report to their offering.

Stribild Introduction to Reinforce HIV/AIDS Revenues as Key Patents Expire

Gilead Science's combination drug Stribild (previously known as the Quad pill) is expected to bolster the HIV/AIDS therapeutics market as a number of significant medications go off-patent over the next few years, states business intelligence provider GBI Research in its latest publication.

Forecasts from the firm's latest report indicate that the global HIV/AIDS therapeutics market will increase in value at a Compound Annual Growth Rate (CAGR) of 7% between the years 2011 and 2018, from $13.5 billion to $21.8 billion.

As a consequence of the on-going patent-cliff, this predicted growth rate is less than the market experienced in previous years. Between 2004 and 2011, the market experienced a more impressive CAGR of 12.5%, but due to the impending expiry of key medications, including Sustiva and Reyataz (both produced by Bristol-Myers Squibb) in 2014 and 2017 respectively, a more modest increase is predicted.

However, the market is not without promise. The multi-class fixed dose combination tablet from Gilead Sciences, Atripla, saw global revenue increase from $2.9 billion in 2010 to $3.2 billion last year, while potential blockbuster Stribild was approved by the US Food and Drug Administration in August of this year and is expected to make a major impact.

Gilead announced Stribild's initial price as $28,500, which is one-third greater than that of Atripla, but with impressive efficacy and strong patient compliance, GBI Research do not expect this higher cost to be a significant barrier to widespread use.

Last year's sales figures show Gilead as being the greatest revenue shareholder of the world's top seven markets, with 36%. With less than half of that number, Bristol-Myers Squibb came second with 16%, while ViiV Healthcare completed the top three with a 13% segment.

This report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Companies Mentioned

- Gilead Sciences, Inc

- GlaxoSmithKline (GSK)

- BMS

- Abbott Laboratories

- Merck

- Johnson & Johnson (J&J)

- Roche

For more information visit http://www.researchandmarkets.com/research/cnk25v/hivaids.
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 23, 2012
Words:495
Previous Article:Research and Markets: Contraceptives Market to 2018.
Next Article:Research and Markets: South Africa Mining Industry - Labor Unrest to Hamper Productivity.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters